{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:53:08Z","timestamp":1689040388345},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11912-022-01250-y","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T05:02:51Z","timestamp":1649653371000},"page":"1121-1131","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies"],"prefix":"10.1007","volume":"24","author":[{"given":"Michael R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"issue":"8","key":"1250_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","volume":"101","author":"NH Fowler","year":"2016","unstructured":"Fowler NH, Cheah CY, Gascoyne RD, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101(5):531\u201340.","journal-title":"Haematologica."},{"issue":"11","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952\u201363.","journal-title":"Blood."},{"key":"1250_CR4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th Edition)","author":"SHCE Swerdlow","year":"2017","unstructured":"Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th Edition). Lyon: IARC; 2017."},{"issue":"3","key":"1250_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3324\/haematol.2011.053199","volume":"97","author":"WJ Plattel","year":"2012","unstructured":"Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2019s lymphoma. Haematologica. 2012;97(3):410\u20135.","journal-title":"Haematologica."},{"issue":"12","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/modpathol.3880473","volume":"14","author":"CV Hedvat","year":"2001","unstructured":"Hedvat CV, Jaffe ES, Qin J, et al. Macrophage-derived chemokine expression in classical Hodgkin\u2019s lymphoma: application of tissue microarrays. Mod Pathol. 2001;14(12):1270\u20136.","journal-title":"Mod Pathol"},{"issue":"4","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ijc.23119","volume":"122","author":"D Aldinucci","year":"2008","unstructured":"Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 2008;122(4):769\u201376.","journal-title":"Int J Cancer"},{"issue":"4","key":"1250_CR8","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","volume":"111","author":"Y Ma","year":"2008","unstructured":"Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339\u201346.","journal-title":"Blood."},{"issue":"12","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","volume":"99","author":"BF Skinnider","year":"2002","unstructured":"Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283\u201397.","journal-title":"Blood."},{"issue":"16","key":"1250_CR10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","volume":"133","author":"ED Hsi","year":"2019","unstructured":"\u2022 Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762\u20135 Cytokine imapct on the TME is well described, but this study shows how this cytokine signature can predict inferior clinical outcomes.","journal-title":"Blood"},{"issue":"2","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","volume":"31","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2013;31(2):256\u201362.","journal-title":"J Clin Oncol"},{"key":"1250_CR12","unstructured":"\u2022\u2022 Jachimowicz RD, Pieper L, Reinke S, et al. Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica. 2020. Despite intensive, aggressive therapy with BEACOPP, there is a subset of patients with a specific TME signature that predicts inferior responsiveness."},{"issue":"4","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","volume":"11","author":"T Alvaro","year":"2005","unstructured":"Alvaro T, Lejeune M, Salvad\u00f3 MT, et al. Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1250_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2005-12-5125","volume":"108","author":"A S\u00e1nchez-Aguilera","year":"2006","unstructured":"S\u00e1nchez-Aguilera A, Montalb\u00e1n C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662\u20138.","journal-title":"Blood."},{"issue":"10","key":"1250_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362(10):875\u201385.","journal-title":"N Engl J Med"},{"issue":"16","key":"1250_CR16","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","volume":"120","author":"KL Tan","year":"2012","unstructured":"Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120(16):3280\u20137.","journal-title":"Blood."},{"issue":"1","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","volume":"14","author":"B Guo","year":"2016","unstructured":"Guo B, Cen H, Tan X, Ke Q. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med. 2016;14(1):159.","journal-title":"BMC Med"},{"issue":"3","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","volume":"141","author":"JL Klein","year":"2014","unstructured":"Klein JL, Nguyen TT, Bien-Willner GA, et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol. 2014;141(3):381\u20137.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjh.15703","volume":"184","author":"AR Gholiha","year":"2019","unstructured":"\u2022 Gholiha AR, Hollander P, Hedstrom G, et al. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. Br J Haematol. 2019;184(2):192\u2013201 B-cells, T-cells, macrophages, and other immune cells are well described prognostically in cHL, this study describes plasma cells as an important component, which is less well described in the literature.","journal-title":"Br J Haematol"},{"issue":"5","key":"1250_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Vetro C, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168(5):689\u2013700.","journal-title":"Br J Haematol"},{"issue":"17","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood."},{"issue":"2","key":"1250_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.seminhematol.2015.01.002","volume":"52","author":"K Dunleavy","year":"2015","unstructured":"Dunleavy K, Steidl C. Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. Semin Hematol. 2015;52(2):119\u201325.","journal-title":"Semin Hematol"},{"issue":"8","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","volume":"132","author":"FZ Cader","year":"2018","unstructured":"Cader FZ, Schackmann RCJ, Hu X, et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment. Blood. 2018;132(8):825\u201336.","journal-title":"Blood."},{"issue":"1","key":"1250_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","volume":"108","author":"RA Roberts","year":"2006","unstructured":"Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311\u20138.","journal-title":"Blood."},{"issue":"2","key":"1250_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","volume":"93","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica. 2008;93(2):193\u2013200.","journal-title":"Haematologica."},{"key":"1250_CR26","unstructured":"\u2022\u2022 Armand P, Engert A, Younes A, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428\u201339 Literature that led to FDA approval of checkpoint inhibitors in cHL and PMBL, which target the TME in these diseases."},{"issue":"9","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol"},{"key":"1250_CR28","doi-asserted-by":"crossref","unstructured":"Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144\u201353 Literature that led to FDA approval of checkpoint inhibitors in cHL and PMBL, which target the TME in these diseases.undefined.","DOI":"10.1182\/blood.2019000324"},{"issue":"6","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"\u2022\u2022 Br\u00f6ckelmann PJ, Goergen H, Keller U, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020;6(6):872\u201380 Data supporting the investigation of moving checkpoint inhibitors into the frontline treatment of early stage, unfavorable, cHL.","journal-title":"JAMA Oncol"},{"issue":"25","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1182\/blood.2020008553","volume":"136","author":"S Reinke","year":"2020","unstructured":"\u2022\u2022 Reinke S, Br\u00f6ckelmann PJ, Iaccarino I, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020;136(25):2851\u201363 Checkpoint inhibitors are approved for use in HL, and this publication defines how a withdrawal of pro-survival factors, rather than a cytotoxic T-cell activation, is how these therapies affect the TME and attack the tumor.","journal-title":"Blood"},{"key":"1250_CR31","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291\u20139 Literature that led to FDA approval of checkpoint inhibitors in cHL and PMBL, which target the TME in these diseases.","DOI":"10.1200\/JCO.19.01389"},{"key":"1250_CR32","doi-asserted-by":"crossref","unstructured":"Calabretta E, Carlo-Stella C. The many facets of CD38 in lymphoma: from tumor-microenvironment cell interactions to acquired resistance to immunotherapy. Cells. 2020;9(4).","DOI":"10.3390\/cells9040802"},{"issue":"3","key":"1250_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","volume":"10","author":"T Aoki","year":"2020","unstructured":"\u2022 Aoki T, Chong LC, Takata K, et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov. 2020;10(3):406\u201321 T-cells with LAG3 expression have been described within the TME of HL, which could suggest a target to improve immunotherapy in HL.","journal-title":"Cancer Discov"},{"issue":"42","key":"1250_CR34","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1073\/pnas.1516107112","volume":"112","author":"JE Janik","year":"2015","unstructured":"Janik JE, Morris JC, O'Mahony D, et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci U S A. 2015;112(42):13045\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Supplement 1","key":"1250_CR35","first-page":"1510","volume":"130","author":"SM Horwitz","year":"2017","unstructured":"Horwitz SM, Hamadani M, Fanale MA, et al. Interim results from a phase 1 study of ADCT-301 (Camidanlumab Tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed\/refractory Hodgkin\/non-Hodgkin lymphoma. Blood. 2017;130(Supplement 1):1510\u20130.","journal-title":"Blood."},{"issue":"20","key":"1250_CR36","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-14-0497","volume":"20","author":"K Dunleavy","year":"2014","unstructured":"Dunleavy K, Roschewski M, Wilson WH. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. Clin Cancer Res. 2014;20(20):5182\u201393.","journal-title":"Clin Cancer Res"},{"issue":"6769","key":"1250_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature."},{"issue":"5","key":"1250_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"15","key":"1250_CR39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"2","key":"1250_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481\u2013494.e415.","journal-title":"Cell."},{"issue":"22","key":"1250_CR41","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"1250_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353\u201364.","journal-title":"Cell."},{"issue":"2","key":"1250_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100(2):238\u201345.","journal-title":"Haematologica."},{"issue":"12","key":"1250_CR44","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","volume":"29","author":"S Ciavarella","year":"2018","unstructured":"\u2022 Ciavarella S, Vegliante MC, Fabbri M, et al. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol. 2018;29(12):2363\u201370 Prior to this publication there was limited data on the prognostic impact of the TME in DLBCL. Myofibroblasts, dendritic cells, and CD4+ T-cells were all found to be associated with improved outcomes, whereas NK cells and plasma cells were associated with inferior outcomes.","journal-title":"Ann Oncol"},{"issue":"4","key":"1250_CR45","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2141.2007.06593.x","volume":"137","author":"S Hasselblom","year":"2007","unstructured":"Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol. 2007;137(4):364\u201373.","journal-title":"Br J Haematol"},{"issue":"6","key":"1250_CR46","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728\u201340.","journal-title":"Cancer Cell"},{"issue":"19","key":"1250_CR47","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193\u2013201.","journal-title":"Blood."},{"issue":"10","key":"1250_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2020006464","volume":"137","author":"GK Griffin","year":"2021","unstructured":"\u2022\u2022 Griffin GK, Weirather JL, Roemer MGM, et al. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell\/histiocyte-rich large B-cell lymphoma. Blood. 2021;137(10):1353\u201364 This aggressive and difficult to treat subtype of DLBCL was found to have PD-L1 expressing TAMs and PD-1+ T cells, which argues for the use of immune checkpoint inhibitors in this disease.","journal-title":"Blood"},{"issue":"2","key":"1250_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clml.2020.10.015","volume":"21","author":"D Chihara","year":"2021","unstructured":"Chihara D, Dunleavy K. Primary central nervous system lymphoma: evolving biologic insights and recent therapeutic advances. Clin Lymphoma Myeloma Leuk. 2021;21(2):73\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1250_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/asheducation-2017.1.556","volume":"2017","author":"JL Rubenstein","year":"2017","unstructured":"Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):556\u201364.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"1250_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2141.2007.06661.x","volume":"138","author":"M Ponzoni","year":"2007","unstructured":"\u2022 Ponzoni M, Berger F, Chassagne-Clement C, et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol. 2007;138(3):316\u201323 Describes insight into PCNSL TME, describing the presence of activated macrophages and reactive T-cells, and the prognostic impact of CXCL13.","journal-title":"Br J Haematol"},{"issue":"4","key":"1250_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487\u2013502.","journal-title":"Br J Haematol"},{"issue":"7","key":"1250_CR53","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","volume":"15","author":"U Vitolo","year":"2014","unstructured":"Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730\u20137.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1250_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1250_CR55","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329\u201338.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1250_CR56","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"\u2022\u2022 Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317\u201328 Phase III clinical trial that unfortunately reported a lack of benefit for R2-CHOP vs R-CHOP, despite favorable results from earlier trials in ABC-type DLBCL.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1250_CR57","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1250_CR58","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, et al. Randomized phase III Trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285\u201395.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1250_CR59","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u2013568.e514.","journal-title":"Cancer Cell"},{"issue":"6","key":"1250_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37(6):481\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1250_CR61","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","volume":"4","author":"C Keane","year":"2020","unstructured":"\u2022 Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4(7):1367\u201377 LAG3 expression in the DLBCL TME could help explain the poor responses noted with checkpoint inhibitors in the disease, and provide a new therapeutic avenue for clinical trials in the future.","journal-title":"Blood Adv"},{"issue":"13","key":"1250_CR62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2019002395","volume":"135","author":"C Carpio","year":"2020","unstructured":"Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996\u20131007.","journal-title":"Blood."},{"key":"1250_CR63","doi-asserted-by":"crossref","unstructured":"Risue\u00f1o A, Hagner PR, Towfic F, et al. Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent. Blood. 2020;135(13):1008\u201318 Avadomide, a novel therapeutic agent in DLBCL, was shown to produce clinical benefit in patients TME that displayed gene expression profiling rich in T-cell, macrophage, and immune\/inflammatory signals.undefined.","DOI":"10.1182\/blood.2019002414"},{"issue":"19","key":"1250_CR64","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"\u2022 Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621\u201333 High levels of monocytic myeloid derived suppressor cells, and high IL-6 and ferritin levels were associated with lack of durable CAR-T response in large B-cell lymphomas.","journal-title":"Blood"},{"issue":"8","key":"1250_CR65","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"9","key":"1250_CR66","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015;112(9):E966\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1250_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833\u2013843 e835.","journal-title":"Cancer Cell"},{"issue":"4","key":"1250_CR68","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol. 2019;30(4):621\u20138.","journal-title":"Ann Oncol"},{"issue":"23","key":"1250_CR69","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071\u20133.","journal-title":"Blood."},{"issue":"1","key":"1250_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.leu.2404426","volume":"21","author":"RJ Bende","year":"2007","unstructured":"Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia. 2007;21(1):18\u201329.","journal-title":"Leukemia."},{"issue":"34","key":"1250_CR71","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","volume":"24","author":"T Alvaro","year":"2006","unstructured":"Alvaro T, Lejeune M, Salvad\u00f3 MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24(34):5350\u20137.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1250_CR72","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369.","journal-title":"N Engl J Med"},{"issue":"21","key":"1250_CR73","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713\u201320.","journal-title":"Blood."},{"issue":"1","key":"1250_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40\u20137.","journal-title":"Blood."},{"issue":"6","key":"1250_CR75","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","volume":"106","author":"P Farinha","year":"2005","unstructured":"Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169\u201374.","journal-title":"Blood."},{"issue":"2","key":"1250_CR76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","volume":"115","author":"P Farinha","year":"2010","unstructured":"Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115(2):289\u201395.","journal-title":"Blood."},{"issue":"21","key":"1250_CR77","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","volume":"131","author":"R K\u00fcppers","year":"2018","unstructured":"\u2022 K\u00fcppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma. Blood. 2018;131(21):2297\u2013306 Important discussion of the interactions between FL cells and TME cells, that lead to survival of tumor cells within the germinal center and BCR signaling.","journal-title":"Blood"},{"issue":"16","key":"1250_CR78","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","volume":"126","author":"R Amin","year":"2015","unstructured":"Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood. 2015;126(16):1911\u201320.","journal-title":"Blood."},{"issue":"5","key":"1250_CR79","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.celrep.2020.107522","volume":"31","author":"D Bararia","year":"2020","unstructured":"\u2022 Bararia D, Hildebrand JA, Stolz S, et al. Cathepsin S Alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Rep. 2020;31(5):107522 Novel genetic alteration that is present in a subset of FL patients, which leads to activation of CD4+ T-cells, release of pro-inflammatory cytokines and growth of FL cells.","journal-title":"Cell Rep"},{"issue":"6","key":"1250_CR80","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"1250_CR81","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/imm.12087","volume":"139","author":"JY Henry","year":"2013","unstructured":"Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs\u00ae immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139(3):377\u201385.","journal-title":"Immunology."},{"issue":"1","key":"1250_CR82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","volume":"126","author":"K Lagrue","year":"2015","unstructured":"Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50\u201360.","journal-title":"Blood."},{"issue":"14","key":"1250_CR83","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"\u2022 Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399 Lenalidomide has a multi-mechanistic action on the TME, and the AUGMENT trial described clear PFS benefit for R2 vs rituximab in R\/R FL, and it was found to have similar PFS compared to rituximab\/chemotherapy in the upfront setting.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1250_CR84","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"\u2022 Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934\u201347 Lenalidomide has a multi-mechanistic action on the TME, and the AUGMENT trial described clear PFS benefit for R2 vs rituximab in R\/R FL, and it was found to have similar PFS compared to rituximab\/chemotherapy in the upfront setting.","journal-title":"N Engl J Med"},{"issue":"23","key":"1250_CR85","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","volume":"36","author":"AK Gopal","year":"2018","unstructured":"Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36(23):2405\u201312.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1250_CR86","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182\u201390.","journal-title":"Blood."},{"key":"1250_CR87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1545.1545","volume-title":"Phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in indolent non-Hodgkin\u2019s lymphoma (iNHL)","author":"JP Sharman","year":"2015","unstructured":"Sharman JP, Klein LM, Boxer M, et al. Phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in indolent non-Hodgkin\u2019s lymphoma (iNHL). Washington, DC: American Society of Hematology; 2015."},{"issue":"20","key":"1250_CR88","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411\u20135.","journal-title":"Blood."},{"issue":"17","key":"1250_CR89","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1182\/bloodadvances.2020001584","volume":"4","author":"N Serrat","year":"2020","unstructured":"\u2022 Serrat N, Guerrero-Hern\u00e1ndez M, Matas-C\u00e9spedes A, et al. PI3K\u03b4 inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Adv. 2020;4(17):4217\u201331 Investigators were able to show idelalisib exerted a general reshaping of the immune microenvironment (interference of CD40\/CD40L pathway, downregulation of proteins critical for B-T-cell synapses, inefficient cross-talk between FL cells and T-follicular helpers) and restore cell dependence on BCL-2. This provides mechanistic rationale to combine venetoclax with PI3K inhibitors in FL.","journal-title":"Blood Adv"},{"issue":"14","key":"1250_CR90","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood-2014-04-569566","volume":"124","author":"J Palomero","year":"2014","unstructured":"Palomero J, Vegliante MC, Rodr\u00edguez ML, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235\u201347.","journal-title":"Blood."},{"issue":"4","key":"1250_CR91","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor \u00c1, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130(4):501\u201313.","journal-title":"Blood."},{"issue":"19","key":"1250_CR92","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113(19):4604\u201313.","journal-title":"Blood."},{"issue":"5","key":"1250_CR93","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","volume":"21","author":"JA Burger","year":"2011","unstructured":"Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011;21(5):308\u201312.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"1250_CR94","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","volume":"136","author":"S Bernard","year":"2015","unstructured":"Bernard S, Danglade D, Gardano L, et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer. 2015;136(12):2761\u201374.","journal-title":"Int J Cancer"},{"issue":"1","key":"1250_CR95","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3324\/haematol.2017.177162","volume":"103","author":"M Rudelius","year":"2018","unstructured":"Rudelius M, Rosenfeldt MT, Leich E, et al. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica. 2018;103(1):116\u201325.","journal-title":"Haematologica."},{"issue":"24","key":"1250_CR96","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128(24):2808\u201318.","journal-title":"Blood."},{"issue":"23","key":"1250_CR97","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1158\/1078-0432.CCR-14-0889","volume":"20","author":"L Nygren","year":"2014","unstructured":"Nygren L, Wasik AM, Baumgartner-Wennerholm S, et al. T-cell levels are prognostic in mantle cell lymphoma. Clin Cancer Res. 2014;20(23):6096\u2013104.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1250_CR98","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107(9):3639\u201346.","journal-title":"Blood."},{"issue":"9","key":"1250_CR99","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3324\/haematol.2012.071340","volume":"98","author":"L Wang","year":"2013","unstructured":"Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013;98(9):1458\u201366.","journal-title":"Haematologica."},{"issue":"6","key":"1250_CR100","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood."},{"issue":"10121","key":"1250_CR101","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet."},{"issue":"16","key":"1250_CR102","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26(16):4216\u201324.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1250_CR103","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"1250_CR104","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2019-127863","volume":"134","author":"M Dreyling","year":"2019","unstructured":"Dreyling M, Ladetto M, Doorduijn JK, et al. Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma - a randomized European MCL Network Trial. Blood. 2019;134(Supplement_1):2816\u20136.","journal-title":"Blood."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01250-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T01:08:35Z","timestamp":1663031315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01250-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01250-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"13 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Michael Cook declares no conflict of interest. Kieron Dunleavy has participated on advisory boards for Astra Zeneca, Beigene, Genmab, Abbvie, Morphosys, Daiichi Sankyo, Genentech and ADC Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}